J. A. Sosman

667 citations

23 papers · 513 indexed · h-index 13

Molecular Biology
Oncology top 10%
Computational Theory and Mathematics top 10%
Pulmonary and Respiratory Medicine
Immunology

Co-authors: Paul B. Chapman Igor Puzanov Grant A. McArthur Keith T. Flaherty K. B. Nolop Reinhard Dummer Caroline Robert John M. Kirkwood
Topics: Melanoma and MAPK Pathways (17 papers)Computational Drug Discovery Methods (9 papers)Cutaneous Melanoma Detection and Management (6 papers)
Cited by: Oncology Molecular Biology Computational Theory and Mathematics
Journals: Journal of Clinical Oncology Melanoma Research Drugs of the Future
Partner nations: United States Netherlands Australia

In The Last Decade

J. A. Sosman

22 papers receiving 500 citations

Peers

Countries citing papers authored by J. A. Sosman

Since Specialization

Citations

This map shows the geographic impact of J. A. Sosman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. A. Sosman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. A. Sosman more than expected).

Fields of papers citing papers by J. A. Sosman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. A. Sosman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. A. Sosman. The network helps show where J. A. Sosman may publish in the future.

Co-authorship network of co-authors of J. A. Sosman

This figure shows the co-authorship network connecting the top 25 collaborators of J. A. Sosman. A scholar is included among the top collaborators of J. A. Sosman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. A. Sosman. J. A. Sosman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of key prognostic factors on long-term overall survival in BRAFV600-mutated metastatic melanoma patients treated with vemurafenib in the BRIM-3 study 2016 ·Melanoma Research ·Axel Hauschild,Paul B. Chapman,Caroline Robert,James Larkin,J.B.A.G. Haanen,A. Ribas,David Hogg,Omid Hamid,P.A. Ascierto,Alberto Testori,Paul Lorigan,R. Dummer,J. A. Sosman,Keith T. Flaherty,Matthew Wongchenko,(unknown),I‐Fen Chang,(unknown),Ivor Caro,Grant A. McArthur	2
2	Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. 2011 ·Journal of Clinical Oncology ·Paul B. Chapman,Axel Hauschild,Caroline Robert,James Larkin,J.B.A.G. Haanen,A. Ribas,David Hogg,Steven O’Day,Paolo A. Ascierto,Alessandro Testori,Paul Lorigan,Reinhard Dummer,J. A. Sosman,Claus Garbe,(unknown),K. B. Nolop,B. Nelson,Jeannie Hou,Keith T. Flaherty,Grant A. McArthur	2
3	BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. 2011 ·Journal of Clinical Oncology ·A. Ribas,(unknown),Lynn M. Schuchter,R. Gonzalez,Anne C. Pavlick,Jeffrey S. Weber,Grant A. McArthur,Thomas E. Hutson,Keith T. Flaherty,Stergios J. Moschos,Donald P. Lawrence,Peter Hersey,Richard Kefford,Bartosz Chmielowski,Igor Puzanov,(unknown),K. B. Nolop,(unknown),Andrew K. Joe,J. A. Sosman	107
4	Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma 2011 ·Paul B. Chapman,Axel Hauschild,Caroline Robert,James Larkin,J.B.A.G. Haanen,A. Ribas,David Hogg,Steven O’Day,Paolo A. Ascierto,Alessandro Testori,Paul Lorigan,Reinhard Dummer,J. A. Sosman,Claus Garbe,(unknown),K. B. Nolop,B. Nelson,Jeannie Hou,Keith T. Flaherty,Grant A. McArthur	13
5	Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation–positive metastatic melanoma patients (pts). 2011 ·Journal of Clinical Oncology ·Grant A. McArthur,Antoni Ribas,Paul B. Chapman,Keith T. Flaherty,(unknown),Igor Puzanov,Katherine L. Nathanson,(unknown),Astrid Koehler,Olivia Spleiss,Gideon Bollag,Wenhui Wu,Kerstin Trunzer,J. A. Sosman	28
6	Vemurafenib 2011 ·Drugs of the Future ·Igor Puzanov,Keith T. Flaherty,J. A. Sosman,Joseph F. Grippo,Fei Su,K. B. Nolop,(unknown),Gideon Bollag	5
7	Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma. 2011 ·Journal of Clinical Oncology ·William H. Sharfman,F. Stephen Hodi,Donald P. Lawrence,K. T. Flaherty,Ravi K. Amaravadi,(unknown),Reinhard Dummer,(unknown),Igor Puzanov,J. A. Sosman,Kathleen M. Dohoney,Lucy Lam,(unknown),(unknown),Oliver Krieter,Michael B. Atkins	38
8	Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy. 2011 ·Journal of Clinical Oncology ·Mario E. Lacouture,Paul B. Chapman,Antoni Ribas,J. A. Sosman,Grant A. McArthur,Keith T. Flaherty,(unknown),Igor Puzanov,K. B. Nolop,(unknown),Olivia Spleiss,Astrid Koehler,Wenhui Wu,Caroline Robert,Axel Hauschild,Dirk Schadendorf,Julia L. Troy,Madeleine Duvic,Kerstin Trunzer	15
9	Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with ^V600EBRAF-mutated melanoma. 2011 ·Journal of Clinical Oncology ·Paul B. Chapman,Axel Hauschild,Caroline Robert,James Larkin,John B.A.G. Haanen,Antoni Ribas,David Hogg,Steven O’Day,Paolo A. Ascierto,Alessandro Testori,Paul Lorigan,Reinhard Dummer,J. A. Sosman,Claus Garbe,(unknown),K. B. Nolop,B. Nelson,Jeannie Hou,Keith T. Flaherty,Grant A. McArthur	19
10	First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma. 2011 ·Journal of Clinical Oncology ·J. A. Sosman,Alex A. Adjei,P. LoRusso,(unknown),Grace K. Dy,(unknown),Bartosz Chmielowski,(unknown),(unknown),Stephanie Faucette,Elena S. Izmailova,Viviana Bozón,A. Ribas	3
11	Evaluation of minimal residual disease (MRD) in peripheral blood (PB) assessed prospectively by RT-PCR for melanoma-associated genes as a prognostic factor for survival in stage III melanoma (Mel) patients (pts) enrolled onto an intergroup adjuvant trial S0008. 2010 ·Journal of Clinical Oncology ·J. A. Sosman,Ju Hyung Moon,(unknown),Lawrence E. Flaherty,Michael B. Atkins,Kim Margolin,John M. Kirkwood,Vernon K. Sondak	1
12	A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. 2010 ·Journal of Clinical Oncology ·Steven O’Day,F. Stephen Hodi,David F. McDermott,Robert Weber,J. A. Sosman,J.B.A.G. Haanen,Xiyu Zhu,Michael Yellin,Axel Hoos,Walter J. Urba	21
13	Early FDG-PET responses to PLX4032 in BRAF-mutant advanced melanoma. 2010 ·Journal of Clinical Oncology ·Grant A. McArthur,Igor Puzanov,A. Ribas,Paul B. Chapman,(unknown),J. A. Sosman,(unknown),K. B. Nolop,Keith T. Flaherty,Rodney J. Hicks	12
14	Randomized phase II trial of sorafenib (SO) with temsirolimus (TEM) or tipifarnib (TIPI) in metastatic melanoma: Southwest Oncology Group Trial S0438. 2010 ·Journal of Clinical Oncology ·Kim Margolin,James Moon,Lawrence E. Flaherty,Christopher D. Lao,Wallace Akerley,J. A. Sosman,John M. Kirkwood,Vernon K. Sondak,(unknown)	2
15	6BA Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032 2009 ·European Journal of Cancer Supplements ·Paul B. Chapman,Igor Puzanov,J. A. Sosman,(unknown),A. Ribas,Grant A. McArthur,(unknown),Joseph F. Grippo,K. B. Nolop,Keith T. Flaherty	21
16	PLX4032, a highly selective ^V600EBRAF kinase inhibitor: Clinical correlation of activity with pharmacokinetic and pharmacodynamic parameters in a phase I trial 2009 ·Journal of Clinical Oncology ·Igor Puzanov,Katherine L. Nathanson,Paul B. Chapman,Xiaoying Xu,J. A. Sosman,Grant A. McArthur,Antoni Ribas,(unknown),Joseph F. Grippo,K. T. Flaherty	18
17	Prognostic role of prior cytokine immunotherapy in outcome of treatment with tremelimumab (CP-675,206) in patients with metastatic melanoma 2008 ·Journal of Clinical Oncology ·C. A. Bulanhagui,Jesús Gómez-Navarro,Scott Antonia,J. A. Sosman,John M. Kirkwood,Bruce G. Redman,Thomas F. Gajewski,A. Ribas,Luis H. Camacho,Dmitri Pavlov	3
18	Phase II trial of combination thalidomide (thal) plus temozolomide (TMZ [TT]), in patients with metastatic malignant melanoma (MMM): Southwest Oncology Group S0508 2008 ·Journal of Clinical Oncology ·Jason Clark,Joon Ho Moon,Laura F. Hutchins,J. A. Sosman,W. Martin Kast,(unknown),(unknown),John A. Thompson,Vernon K. Sondak	6
19	VEGF-Trap (V-T) overcomes defects in dendritic cell (DC) differentiation without improvement in antigen-specific immune responses 2007 ·Journal of Clinical Oncology ·J. A. Sosman,Ingo Fricke,Noweeda Mirza,Jakob Dupont,(unknown),Andrew M. Jackson,Bonnie LaFleur,Dmitry I. Gabrilovich	0
20	Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. 1997 ·PubMed ·Janice P. Dutcher,Richard I. Fisher,Geoffrey R. Weiss,Frederick R. Aronson,Kim Margolin,Arthur C. Louie,J W Mier,(unknown),J. A. Sosman,John R. Eckardt,Mary Lou Ernest,James H. Doroshow,Michael B. Atkins	49

About J. A. Sosman

J. A. Sosman is a scholar working on Computational Theory and Mathematics, Oncology and Organic Chemistry, having authored 23 papers that have together received 513 indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (17 papers), Computational Drug Discovery Methods (9 papers) and Cutaneous Melanoma Detection and Management (6 papers). The work is most often cited by research in Oncology (395 citations), Molecular Biology (403 citations) and Computational Theory and Mathematics (75 citations). J. A. Sosman has collaborated with scholars based in United States, Netherlands and Australia. Frequent co-authors include Paul B. Chapman, Igor Puzanov, Grant A. McArthur, Keith T. Flaherty, K. B. Nolop, Reinhard Dummer, Caroline Robert, John M. Kirkwood, C. Morris and Lars Bastholt. Their work appears in journals such as Journal of Clinical Oncology, Melanoma Research and Drugs of the Future.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact